Should You Buy the Post-Earnings Plunge in CAVA Stock?

CAVA's stock tumbled nearly 16.6% following its fiscal Q2 2025 earnings, as investors reacted to signs of slowing demand and a trimmed full-year EBITDA forecast. While the company beat profit expectations, revenue of $280.6 million and 2.1% same-store sales growth both missed analyst forecasts, indicating a significant deceleration from previous robust trends. This slowdown, particularly after a strong initial period, combined with CAVA's premium valuation, has prompted investor scrutiny regarding its consistent growth prospects.

Analysis

CAVA's stock experienced a significant 16.6% decline following its fiscal Q2 2025 earnings release, as investor focus shifted from a profit beat to clear signs of decelerating growth and a reduced full-year EBITDA forecast. The company's revenue rose 20.2% year-over-year to $280.6 million, missing analyst expectations of $286.6 million. More critically, same-store sales growth of 2.1% fell substantially short of the 6.1% forecast, signaling a material slowdown. Management attributed this change in pace to the anniversary of a successful grilled steak launch, suggesting difficulty in lapping prior-year strength. This performance miss is particularly concerning given CAVA's premium valuation, trading at 126.40 times forward-adjusted earnings and 6.93 times sales. The combination of slowing top-line momentum and a trimmed profitability outlook has justifiably unsettled investors, calling into question the high growth trajectory that previously supported its rich valuation and leading to a 23.5% stock price drop in the past month.

Key Decisions for Investors

• Given the stock's premium valuation, investors should recognize its heightened sensitivity to any further deceleration in growth, as the market is no longer pricing in flawless execution.
• Closely monitor same-store sales and traffic trends in subsequent quarters to determine if the Q2 slowdown is a temporary issue from lapping a product launch or the start of a sustained moderation.
• While the sharp sell-off toward the 52-week low may present a potential entry point, the trimmed EBITDA outlook and missed growth metrics introduce significant risk, warranting caution for those seeking consistent growth.